The company has complete production functions, can produce more than 30 dosage forms, can produce more than 300 kinds of quasi-brand-name drugs of traditional Chinese medicine, and has more than 20 exclusive varieties. * * * There are 8 quasi-brand-name drugs of traditional Chinese medicine/KLOC-0 selected in the national essential drugs list, and 37 varieties selected in the national medical insurance list, among which Ma Yinglong Musk Hemorrhoid Ointment, Musk hemorrhoids suppository, Dragon Ball Ointment and Ma Yinglong Babao Eye Ointment are exclusive products of the company. The production equipment is advanced, and the technical level of main product lines and supporting facilities has been at the leading level in China.
Around the core positioning, the company carried out a series of drug research and development. At present, there are 7 varieties of anorectal hemorrhoid treatment products and 3 hemorrhoid treatment projects under research, covering ointment, suppository, oral tablets of western medicine, oral tablets of traditional Chinese medicine, lotion, capsule, cream gel, aerosol, powder, granules and other dosage forms. There are 6 varieties of anorectal hemorrhoids treatment, and 8 other projects are under study. The company also developed a series of eye care cosmeceuticals and actively entered the cosmeceuticals market. At present, there are 1 1 research projects.
At present, the company has a technical team with neat staff, reasonable structure and complementary advantages, as well as a group of academic leaders engaged in drug synthesis, traditional Chinese medicine extraction, pharmaceutical engineering, pharmacology and toxicology, clinical trial evaluation and other research. The company has established long-term strategic cooperative relations with many scientific research institutions such as Peking University Pharmaceutical University and China Pharmaceutical University. Approved by the Ministry of Personnel, the company and Peking University * * * set up a postdoctoral workstation. In 2009, the Technology Center of Ma Yinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by the National Development and Reform Commission, the Ministry of Science and Technology and other five ministries and commissions, and the Ma Yinglong innovative drug research and development team was recognized as the first batch of "Hubei Key Industry Innovation Team" by the Organization Department of Hubei Provincial Party Committee.
According to the statistics of Southern Institute of Pharmaceutical Economics of the State Administration of Pharmaceutical Products, Ma Yinglong has a share of over 40% in the retail market of hemorrhoid drugs and is the first brand in the field of hemorrhoid treatment.
The company has established a relatively complete marketing management system and a nationwide marketing network platform, and established long-term cooperative relations with more than 300 enterprises at the forefront of domestic pharmaceutical circulation. Products are exported to Southeast Asia, Europe and America.
Ma Yinglong and its subsidiaries have passed the GMP and GSP quality management standard system certification of the State Pharmaceutical Products Administration respectively, and obtained ISO 14000 and OHSAS 18000 certification issued by SGS, which is the first time to realize the "three certifications" in the pharmaceutical industry. In the list of "Top 500 Most Valuable Brands in China" jointly selected by World Brand Lab and World Managers Weekly in 20 10, Ma Yinglong ranked 2 10, with a brand value of 432 1 100 million yuan. In 2005, Ma Yinglong won the title of "the most influential hemorrhoid medicine brand in China" in the joint selection of six public media, including People's Daily, China Corporate Culture Promotion Association and China Quality and Brand Magazine. In 2006, Ma Yinglong was recognized as "China Famous Trademark" by the State Administration for Industry and Commerce, and became the only "China Famous Trademark" in the field of hemorrhoid treatment in China. In 2009, Ma Yinglong was selected as "China OTC Brand Enterprise 15 Top" by China OTC Association.
The company's stock was listed on the Shanghai Stock Exchange in 2004, and it obtained the channel of continuous financing and the platform of standardized operation. The company's shares were selected as sample shares of corporate governance index of listed companies in China and social responsibility index of Shanghai Stock Exchange by Shanghai Stock Exchange and China Securities Index Company. The company won the "Excellent Board Award" and "Listed Company with Most Attention to Shareholders' Rights and Interests", indicating that the corporate governance level has been highly recognized by the public, securities institutions and experts.